We are an AI biotech specializing in drug development based on transcriptomic database. We strive to develop treatments for intractable and rare disease both in oncology and non-oncology space. We partner with pharmaceutical companies and i) identify the optimal indications of NCE under development, ii) identify the proper indications for clinical stage failed compounds, iii) screen combination drugs that can significantly increase the efficacy synergistically, iv) finding the optimal cancer biomarker, and v) identifying the primary site for carcinoma of unknown primary. While our AI technology offers platform to minimize cost, time, and risk of clinical failure for drug candidates, our desire to provide alternative cost competitive treatments for patients with rare and intractable disease are embedded in everyone at ONCOCROSS. Accelerate Drug Development with ONCOCROSS.
We're tracking ONCOCROSS Co., Ltd.'s market expansion
How ONCOCROSS Co., Ltd.'s international expansion compares to its competitors
ONCOCROSS Co., Ltd.YouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 ONCOCROSS Co., Ltd.You | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Oncocross CEO Kim Irang aims for profitability by 2027, leveraging AI platform RAPTOR for drug repurposing and new indications discovery. The company plans IPO to raise 14.4-17.5 billion won.
FDA's plan to phase out animal testing boosts interest in AI-based drug discovery platforms like OncoX, which uses AI for toxicity prediction and drug repurposing.
Oncocross reported a 64.4% decrease in revenue and increased losses for 2025. The company cited reduced new orders for drug evaluation services and increased costs for AI platform upgrades.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about ONCOCROSS Co., Ltd.'s business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
